Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 07/18 05:35:23 pm
4404 GBp   +0.86%
07/18SHIRE : Form 8.5 (EPT/RI) - Shire plc amendment
PU
07/18SHIRE : Form 8.3 -
PU
07/18SHIRE : Form 8.5 (EPT/RI) - Replaces SHIRE PLC
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Shire plc Shire Plc : Block Listing Interim Review -2-

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/24/2017 | 04:16pm CEST
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                        769,615 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                           408,873 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                       360,742 
 
 
 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Employee Stock Purchase 
Name of scheme:                                                 Plan 
                                                                November 23, 
Period of return:                     From:                     2016           To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                        244,057 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                             6,359 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                       237,698 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Long Term Incentive Plan 
Name of scheme:                                                 2015 
                                                                November 23, 
Period of return:                     From:                     2016          To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                      2,836,412 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                           149,340 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                     2,687,072 
 
 
 
 
Name of applicant:                                              Shire plc 
                                                                Shire Global Employee Stock 
Name of scheme:                                                 Purchase Plan 
                                                                November 23, 
Period of return:                     From:                     2016          To:   May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                      1,604,243 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                             3,400 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                     1,600,843 
 
 
 
 
Name of applicant:                                              Shire plc 
Name of scheme:                                                 Baxalta Exchange Awards 
                                                                November 23, 
Period of return:                     From:                     2016           To:  May 22, 2017 
Balance of unallotted securities under scheme(s) from 
 previous return:                                                                     20,488,204 
Plus: The amount by which the block scheme(s) has 
 been increased since the date of the last return (if 
 any increase has been applied for):                                                         Nil 
Less: Number of securities issued/allotted under scheme(s) 
 during period (see LR3.5.7G):                                                         2,492,337 
Equals: Balance under scheme(s) not yet issued/allotted 
 at end of period:                                                                    17,995,867 
 
 
 
 
Name of contact:               Sarah Rixon, Company Secretarial Assistant 
Telephone number of contact:                                 01256 894000 
 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             [email protected]         +1 781 482 9018 
Robert Coates        [email protected]      +44 203 549 0874 
Media 
Lisa Adler           [email protected]    +1 617 588 8607 
Katie Joyce          [email protected]        +1 781 482 2779 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the global leader in serving patients with rare diseases. We 
strive to develop best-in-class therapies across a core of rare disease 
areas including hematology, immunology, genetic diseases, neuroscience, 
and internal medicine with growing therapeutic areas in ophthalmics and 
oncology. Our diversified capabilities enable us to reach patients in 
more than 100 countries who are struggling to live their lives to the 
fullest. 
 
   We feel a strong sense of urgency to address unmet medical needs and 
work tirelessly to improve people's lives with medicines that have a 
meaningful impact on patients and all who support them on their journey. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
07/18SHIRE : Form 8.5 (EPT/RI) - Shire plc amendment
PU
07/18SHIRE : Form 8.3 -
PU
07/18SHIRE : Form 8.5 (EPT/RI) - Replaces SHIRE PLC
PU
07/18SHIRE : Form 8.3 - Shire plc
PU
07/18SHIRE : Form 8.5 (EPT/RI) - SHIRE PLC
PU
07/18SHIRE : Form 8.5 (EPT/NON-RI) - SHIRE PLC
PU
07/18SHIRE : Form 8.5 - Shire Plc
PU
07/18SHIRE : Form 8.3 - Takeda Pharmaceutical Company Limited
PU
07/18SHIRE : Form 8.5 (EPT/RI)- Shire plc
PU
07/18SHIRE : argenx receives milestone payment from strategic collaboration with Shir..
AQ
More news
News from SeekingAlpha
07/16DIVIDEND GROWTH 50 : Income Up Nearly 10%, Led By Kinder Morgan (Seriously!) 
07/16Merger Arbitrage Mondays - July 16, 2018 
07/12Drug prices still marching upward - Bloomberg 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned..